UNASSIGNED: Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available before and during acetazolamide treatment (n=22).
UNASSIGNED: Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide.
UNASSIGNED: Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.
■涉及单个三级医疗中心的回顾性图表审查。确定了34名患有明确或可能的PTCS的儿童。分析仅限于在乙酰唑胺治疗之前和期间可获得人体测量数据的个体(n=22)。
■一半的个体(n=11/22)显示BMIZ得分下降。63%(n=14/22)在使用乙酰唑胺治疗期间显示身高Z评分降低;在这14名具有完整数据的儿童中,有6名,图3显示在停止乙酰唑胺后高度Z-评分的至少部分恢复。
■乙酰唑胺可能与某些接受儿童PTCS治疗的儿童的生长抑制有关。在某些情况下,一旦停止乙酰唑胺,生长抑制似乎逆转。